À retenir
In a pilot trial of 50 adults treated for hypertension, an 8-week just-in-time app (LowSalt4Life) reduced spot-urine-estimated sodium excretion by 462 mg versus a 381 mg change with usual advice (P=0.03), but blood pressure did not differ significantly (P=0.12). The trial was tiny and open-label, and the measures disagreed.
Study design
Essai randomisé
Reading basis
Published abstract
Reading focus
Comparator & uncertainty
Cette explication éditoriale existe en anglais, chinois simplifié et chinois traditionnel. Cette interface affiche la lecture en anglais.
Question de recherche
High sodium intake is a major public health problem and is tied to high blood pressure and cardiovascular risk. The authors tested whether LowSalt4Life, a just-in-time adaptive mobile app, reduces sodium intake in adults being treated for hypertension.
Population et méthode
Single-center, prospective, open-label randomized controlled pilot trial. 50 adults aged 18 or older under treatment for hypertension were randomized 1:1, stratified by gender, to the App group (LowSalt4Life) or the No App group (usual dietary advice) for 8 weeks. The primary endpoint was the change in 24-hour urinary sodium excretion estimated from a spot urine sample with the Kawasaki equation, analyzed with unpaired two-sided t tests. Secondary outcomes were sodium intake from a food frequency questionnaire (FFQ) and from 24-hour dietary recall, 24-hour urinary sodium excretion, blood pressure and self-reported confidence in following a low-sodium diet.
Résultats
The authors’ reported results. Read each estimate with its population and uncertainty.
- 1Primary endpoint: Kawasaki-estimated 24-hour urinary sodium excretion fell by 462 mg (SD 1220) in the App group; the No App group's change was 381 mg (SD 1460; the abstract gives no sign), P=0.03.
- 2Another urinary sodium measure, the change in 24-hour urinary sodium excretion, was -637 mg (SD 1524) with the app and -322 mg (SD 1485) without it (P=0.47), so this measure showed no clear difference.
- 3Estimated sodium intake fell by 1537 mg (SD 2693) by 24-hour dietary recall and by 1553 mg (SD 1764) by FFQ with the app, versus 233 mg (SD 2150) and 515 mg (SD 1081) without it; P=0.07 for dietary recall and P=0.01 for the FFQ.
- 4Systolic blood pressure changed by -7.5 mm Hg with the app and -0.7 mm Hg without it (P=0.12), and confidence in following a low-sodium diet did not differ significantly between groups.
Limites et incertitude
- 1Only 50 participants in a pilot: the systolic difference (-7.5 mm Hg with the app, -0.7 mm Hg without; P=0.12) is imprecise and the trial is too small to settle the blood pressure question.
- 2Open-label, so participants knew their group, which can bias self-reported intake measures such as the FFQ and dietary recall.
- 3Results disagree across measures: significant for the spot-urine estimate and the FFQ, not significant for 24-hour urinary sodium excretion or dietary recall, and the abstract does not mention adjustment for multiple testing.
- 4The primary endpoint is an equation-based estimate from a spot urine sample, not a full 24-hour collection; 8 weeks at a single center leaves durability and generalizability unknown. This reading is based on the abstract only.
Mise en perspective
In this small pilot, an app giving timely low-sodium guidance seemed to lower estimated sodium on some measures but not others, and the blood pressure difference was not statistically significant. It is an early signal; it does not show that the app improves blood pressure or that results last beyond 8 weeks. If you are being treated for hypertension, talk with your clinician before making big diet changes.
Vos données
Sodium is hard to measure at home, and this trial shows why: the urine estimate, the FFQ and the dietary recall did not agree. A food log or app that tracks sodium per meal is a rough guide, so judge changes over weeks rather than days. The more direct check is a home blood pressure cuff, read at the same times each day, with weekly averages compared before and after you cut back.
Comprendre ce type de preuve
Randomisation can support causal inference, but check allocation, blinding, missing outcomes, follow-up and the actual comparator. A trial label alone does not establish high certainty.
Résumé structuré des auteurs English
Le résumé original en anglais est reproduit avec attribution sous la licence ouverte indiquée. Il s’agit d’une source, pas d’une interprétation MoveVitals. L’analyse préparée figure ci-dessus ; vérifiez les conclusions importantes dans la source.
Background
High dietary sodium intake is a significant public health problem in the United States. High sodium consumption is associated with high blood pressure and high risk of cardiovascular disease.
Objective
The aim of this study was to evaluate the effect of a just-in-time adaptive mobile app intervention, namely, LowSalt4Life, on reducing sodium intake in adults with hypertension.
Methods
In this study, 50 participants aged ≥18 years who were under treatment for hypertension were randomized (1:1, stratified by gender) into 2 groups, namely, the App group (LowSalt4Life intervention) and the No App group (usual dietary advice) in a single-center, prospective, open-label randomized controlled trial for 8 weeks. The primary endpoint was the change in the 24-hour urinary sodium excretion estimated from spot urine by using the Kawasaki equation, which was analyzed using unpaired two-sided t tests. Secondary outcomes included the change in the sodium intake measured by the food frequency questionnaire (FFQ), the 24-hour urinary sodium excretion, blood pressure levels, and the self-reported confidence in following a low-sodium diet.
Results
From baseline to week 8, there was a significant reduction in the Kawasaki-estimated 24-hour urinary sodium excretion calculated from spot urine in the App group compared to that in the No App group (-462 [SD 1220] mg vs 381 [SD 1460] mg, respectively; P=.03). The change in the 24-hour urinary sodium excretion was -637 (SD 1524) mg in the App group and -322 (SD 1485) mg in the No App group (P=.47). The changes in the estimated sodium intake as measured by 24-hour dietary recall and by FFQ in the App group were -1537 (SD 2693) mg and -1553 (SD 1764) mg while those in the No App group were -233 (SD 2150) mg and -515 (SD 1081) mg, respectively (P=.07 and P=.01, respectively). The systolic blood pressure change from baseline to week 8 in the App group was -7.5 mmHg while that in the No App group was -0.7 mmHg (P=.12), but the self-confidence in following a low-sodium diet was not significantly different between the 2 groups.
Conclusions
This study shows that a contextual just-in-time mobile app intervention resulted in a greater reduction in the dietary sodium intake in adults with hypertension than that in the control group over a 8-week period, as measured by the estimated 24-hour urinary sodium excretion from spot urine and FFQ. The intervention group did not show a significant difference from the control group in the self-confidence in following a low sodium diet and in the 24-hour urinary sodium excretion or dietary intake of sodium as measured by the 24-hour dietary recall. A larger clinical trial is warranted to further elucidate the effects of the LowSalt4Life intervention on sodium intake and blood pressure levels in adults with hypertension.
Trial registration
ClinicalTrials.gov NCT03099343; https://clinicaltrials.gov/ct2/show/NCT03099343.
International registered report identifier (irrid)
RR2-10.2196/11282.
Sources et attribution
Effects of a Novel Contextual Just-In-Time Mobile App Intervention (LowSalt4Life) on Sodium Intake in Adults With Hypertension: Pilot Randomized Controlled Trial.
Dorsch MP, Cornellier ML, Poggi AD, Bilgen F, Chen P, Wu C, An LC, Hummel SL.
JMIR mHealth and uHealth · 2020-08-10
DOI: 10.2196/16696 ↗PubMed · 32663139 ↗Europe PMC · Licence indiquée: cc by ↗Abstract © the original authors, reproduced under the recorded open licence. Translations support reading; use the English record to check terminology and numerical results. Our methodological interpretation is separate from the authors’ conclusions.
Interprétation éditoriale MoveVitals · contenu éducatif · aucune évaluation clinique individuelle enregistrée
Sources vérifiées 2026-11-01
Guides pratiques
À lire ensemble
Disrupted daily rest-activity rhythm is linked to higher mortality in 109,365 people
Across seven observational studies with 109,365 participants, a weaker day-night activity contrast (lower relative amplitude) was associated with higher cardiovascular mortality (hazard ratio [HR] 1.50, 95% CI 1.13 to 1.98) and all-cause mortality (HR 1.46, 95% CI 1.27 to 1.68). The evidence base is small and observational, so it cannot show that improving the rhythm lowers risk, and illness may itself disturb the rhythm.
Journal of the American Heart Association
Five exercise types lowered resting blood pressure, isometric training the most
Pooling 270 randomised trials with 15,827 participants, aerobic, resistance, combined, interval and isometric training all lowered resting blood pressure compared with non-intervention controls (P<0.001 for each), with the largest fall for isometric training: 8.24 mm Hg systolic and 4.00 mm Hg diastolic. The ranking between modes is partly indirect and the trials differ, so it is not a personal prescription.
British Journal of Sports Medicine
A salt substitute lowered stroke, major cardiovascular events and death in rural China
In 20,995 people in 600 rural Chinese villages who had a history of stroke or were 60 or older with high blood pressure, a salt substitute (75% sodium chloride, 25% potassium chloride) lowered the stroke rate versus regular salt over a mean 4.74 years: 29.14 versus 33.65 events per 1000 person-years (rate ratio 0.86, 95% CI 0.77 to 0.96; P = 0.006). Death was also lower (rate ratio 0.88) and serious hyperkalemia events were not significantly higher, but the trial was open-label and set in rural China.
The New England Journal of Medicine
Apple Watch irregular-pulse alerts were rare; 34% of those tested had atrial fibrillation
Among 419,297 Apple Watch users with no known atrial fibrillation (AF), 0.52% received an irregular-pulse alert, and 34% of the 450 who returned a usable ECG patch had AF (97.5% CI 29 to 39). Alerts that coincided with patch recording matched AF with a positive predictive value of 0.84 (95% CI 0.76 to 0.92), but only 20.8% of alerted people returned a patch and nobody without an alert was monitored, so a quiet watch does not rule AF out.
The New England Journal of Medicine

